Literature DB >> 3821785

Recent advances in the pathogenesis of diabetic neuropathy.

P A Low.   

Abstract

Recent advances in the understanding of the pathogenesis of diabetic neuropathy have been made in six areas. There is support for the notion that a reduction in nerve free myoinositol may be responsible in part for the nerve conduction slowing in diabetic neuropathy. There is further evidence of microvascular abnormalities, including morphometric evidence of multifocal fiber loss and of capillary changes in biopsied sural nerve. There is evidence of endoneurial hypoxia, including the findings of reduced nerve blood flow and endoneurial oxygen tensions in chronic experimental diabetic neuropathy (EDN). The major mechanisms of resistance to ischemic conduction failure (RICF) is the marked increase in nerve energy substrates. Recent studies provide certain insights into clinical characteristics of human diabetic neuropathy (HDN), including the asymmetric pattern of HDN, the paradox between liability to pressure palsies and RICF, and insulin-related acute painful neuropathy. The suggested pathogenetic scheme incorporates the notion that once hypoxia is established, it may start a vicious cycle of further capillary damage and escalating hypoxia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3821785     DOI: 10.1002/mus.880100204

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  24 in total

Review 1.  Aldose reductase inhibitors in the treatment of diabetic neuropathy. A review of the rationale and clinical evidence.

Authors:  E A Masson; A J Boulton
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

2.  Treatment of diabetic polyneuropathy with the neurotrophic peptide ORG 2766.

Authors:  G D Valk; A C Kappelle; A M Tjon-A-Tsien; B Bravenboer; K Bakker; R P Michels; C M Groenhout; F W Bertelsmann
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

3.  Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine.

Authors:  M Sagara; J Satoh; R Wada; S Yagihashi; K Takahashi; M Fukuzawa; G Muto; Y Muto; T Toyota
Journal:  Diabetologia       Date:  1996-03       Impact factor: 10.122

4.  A neuropathic deficit, decreased sweating, is prevented and ameliorated by euglycemia in streptozocin diabetes in rats.

Authors:  C Cardone; P J Dyck
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

Review 5.  Diabetic neuropathy part 1: overview and symmetric phenotypes.

Authors:  Mamatha Pasnoor; Mazen M Dimachkie; Patricia Kluding; Richard J Barohn
Journal:  Neurol Clin       Date:  2013-03-15       Impact factor: 3.806

6.  Resistance to ischaemic conduction failure in chronic hypoxaemia and diabetes.

Authors:  K K Hampton; S M Alani; J I Wilson; D E Price
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-11       Impact factor: 10.154

7.  Is resistance to ischaemic conduction failure induced by hypoxia?

Authors:  E A Masson; S E Church; A A Woodcock; S P Hanley; A J Boulton
Journal:  Diabetologia       Date:  1988-10       Impact factor: 10.122

Review 8.  The efficacy of aldose reductase inhibitors in the management of diabetic complications. Comparison with intensive insulin treatment and pancreatic transplantation.

Authors:  J M van Gerven; A M Tjon-A-Tsien
Journal:  Drugs Aging       Date:  1995-01       Impact factor: 3.923

9.  The effects of neuropeptide Y on skeletal muscle contractile properties in streptozotocin diabetic rats.

Authors:  M Ljubisavljevic; A Qureshi; N Nagelkerke
Journal:  Mol Cell Biochem       Date:  2009-07-19       Impact factor: 3.396

Review 10.  Diabetic neuropathy in the elderly.

Authors:  A A Sima; D A Greene
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.